




The International Congress on
**CONTROVERSIES IN
STEM CELL TRANSPLANTATION
AND CELLULAR THERAPIES**



BERLIN • GERMANY • SEPTEMBER 8-11, 2011

2nd ANNOUNCEMENT & CALL FOR ABSTRACTS

ABSTRACT DEADLINE - MAY 10, 2011



www.comtecmed.com/costem | costem@comtecmed.com

A comprehensive Congress fully devoted to clinical debates and controversial issues in the fields of Stem Cell Transplantation and Cellular Therapies



The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
Berlin, Germany • September 8-11, 2011

Dear Friends and Colleagues,

Over the years, the fields of Stem Cell Transplantation and Cellular Therapies have undergone enormous expansion in clinical trials and basic research as well as in cutting-edge technology.

The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) will function as an exclusive forum for international experts to share and compare experiences, in order to outline the right treatment for patients. This innovative Congress is unique in its explicit focus on resolving controversies in best clinical care of patients.

Academically, the Congress will raise the most dynamic and controversial topics facing clinicians in an exciting and engaging debate forum. The Congress will promote excellence by seeking to shed light on ongoing and challenging debates and to bridge gaps between the expansion of information and its consolidation in clinical practice.

Participants will have the advantage of discussing and debating these unresolved issues with leading world experts in all fields of Stem Cell Transplantation and Cellular Therapies. Allowing ample time for speaker-audience discussion, the Congress aims at reaching up-to-date and agreed-upon answers to ongoing debates even when proof is lacking, through evidence-based medicine and expert opinion.

We invite you to take part in the **COSTEM Congress** which is intended as the inaugural event of future editions.

We look forward to an exciting event in the beautiful city of Berlin.

Prof. N. Kröger and Prof. A. Nagler

Co-Chairpersons

On behalf of the Organizing Committee





The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
Berlin, Germany • September 8-11, 2011

CO-CHAIRPERSONS



Nicolaus Kröger
Germany



Arnon Nagler
Israel

ORGANIZING COMMITTEE

Jürgen Finke
Germany

Alejandro Madrigal
UK

Dietger Niederwieser
Germany

Jacob M. Rowe
Israel

LOCAL ORGANIZING COMMITTEE

Renate Arnold
Germany

Lutz Uharek
Germany

FACULTY (preliminary list)

J.F. Apperley, *UK*
W. Arcese, *Italy*
R. Arnold, *Germany*
A. Bacigalupo, *Italy*
P. Bader, *Germany*
B. Barlogie, *USA*
M. Bishop, *USA*
D. Blaise, *France*
M. Bornhäuser, *Germany*
C. Brunstein, *USA*
M. Cavazzana-Calvo, *France*
F. Ciceri, *Italy*
P. Corradini, *Italy*
M. de Lima, *USA*
T. de Witte, *The Netherlands*
H.J. Deeg, *USA*
V. Diehl, *Germany*
G. Ehninger, *Germany*
H. Einsele, *Germany*
J.H.F. Falkenburg, *The Netherlands*

J.L. Ferrara, *USA*
J. Finke, *Germany*
G. Gahrton, *Sweden*
S.A. Giral, *USA*
C. Gisselbrecht, *France*
E. Gluckman, *France*
H. Goldschmidt, *Germany*
H. Greinix, *Austria*
R. Handgretinger, *Germany*
J.L. Harousseau, *France*
R. Hehlmann, *Germany*
D. Hoelzer, *Germany*
E. Holler, *Germany*
H.J. Kolb, *Germany*
K. Le Blanc, *Sweden*
P. Ljungman, *Sweden*
F. Locatelli, *Italy*
S. Mackinnon, *UK*
A. Madrigal, *UK*
M.F. Martelli, *Italy*
G. Maschmeyer, *Germany*

R.A. Mesa, *USA*
J. Miller, *USA*
M. Mohty, *France*
D. Niederwieser, *Germany*
E. Olavarria, *Spain*
J.R. Passweg, *Switzerland*
C. Peters, *Austria*
Y. Reisner, *Israel*
S. Riddell, *USA*
V. Rocha, *France*
J.M. Rowe, *Israel*
J.F. San Miguel, *Spain*
G. Sanz, *Spain*
A. Shimoni, *Israel*
J. Sierra, *Spain*
S. Slavin, *Israel*
G. Socié, *France*
R. Storb, *USA*
A. Sureda, *Spain*
L. Uharek, *Germany*
A.R. Zander, *Germany*



The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
Berlin, Germany • September 8-11, 2011

PRELIMINARY SCIENTIFIC PROGRAM

FRIDAY, SEPTEMBER 9, 2011

HALL A

08:30-10:00 **PLENARY SESSION 1: SCT IN MYELOMA AND MDS**

Chairs: N. Kröger, Germany &
A. Nagler, Israel

08:30-08:35 Co-Chairpersons Introduction

AUTOLOGOUS SCT AS FIRST LINE TREATMENT?

08:35-08:45 Yes: J.L. Harousseau, France

08:45-08:55 No:

08:55-09:15 Discussion

ALLO SCT IN ELDERLY PATIENTS (>60 Y) WITH MDS

09:15-09:30 Yes: T. de Witte, The Netherlands

09:30-09:45 No:

09:45-10:00 Discussion

10:00-10:30 **Coffee Break**

10:30-12:00 **SESSION 2**

RELAPSE PREVENTION: PROPHYLACTIC DLI?

Chair: M. Bishop, USA

10:30-10:45 Yes: H.J. Kolb, Germany

10:45-11:00 No: A. Bacigalupo, Italy

11:00-11:15 Discussion

CAN WE PREVENT RELAPSE BY NOVEL CONDITIONING REGIMEN?

Chair: S.A. Giralt, USA

11:15-11:30 Yes: M. de Lima, USA

11:30-11:45 No: A. Shimoni, Israel

11:45-12:00 Discussion

12:00-13:00 **Lunch**

13:00-14:00 To be announced

14:00-15:30 **SESSION 4**

SECOND ALLO FOR RELAPSE

Chair: J. Miller, USA

14:00-14:15 Yes: S. Slavin, Israel

14:15-14:30 No: M. Bishop, USA

14:30-14:45 Discussion

DONOR SELECTION TO PREVENT RELAPSE

Chair: M. de Lima

14:45-15:00 According to KIR typing: J. Miller, USA

15:00-15:15 According to HLA typing:

A. Madrigal, UK

15:15-15:30 Discussion

15:30-16:00 **Coffee Break**

16:00-17:30 **SESSION 6**

ALLO SCT FOR REFRACTORY LEUKEMIA

Chair: J.M. Rowe, Israel

16:00-16:15 Yes: M. Mohty, France

16:15-16:30 No: D. Blaise, France

16:30-16:45 Discussion

SHOULD ALL MRD POSITIVE PATIENTS RECEIVE ALLO SCT?

Chair: C. Peters, Austria

16:45-17:00 Yes: P. Bader, Germany

17:00-17:15 No:

17:15-17:30 Discussion



The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
Berlin, Germany • September 8-11, 2011

PRELIMINARY SCIENTIFIC PROGRAM

FRIDAY, SEPTEMBER 9, 2011

HALL B

10:30-12:00 SESSION 3

INDICATION FOR UNRELATED ALLO SCT IN 1. CR AML

Chair: M. Mohty, France

10:30-10:45 Yes: D. Niederwieser, Germany

10:45-11:00 No: J. Sierra, Spain

11:00-11:15 Discussion

ALLOGENEIC SCT FOR CML AFTER FAILURE TO 1. TKI

Chair: R. Hehlmann, Germany

11:15-11:30 Yes: E. Olavarria, Spain

11:30-11:45 No: J.F. Apperley, UK

11:45-12:00 Discussion

12:00-13:00 Lunch

14:00-15:30 SESSION 5

MUD OR IMMUNOSUPPRESSIVE THERAPY FOR APLASTIC ANEMIA

Chair: J. Finke, Germany

14:00-14:15 MUD: J.R. Passweg, Switzerland

14:15-14:30 IS:

14:30-14:45 Discussion

AUTOLOGOUS SCT FOR AUTOIMMUNE DISEASE

Chair: R. Arnold, Germany

14:45-15:00 Yes:

15:00-15:15 No:

15:15-15:30 Discussion

15:30-16:00 Coffee Break

16:00-17:30 SESSION 7

CAN TREG PREVENT GVHD WITHOUT LOSING GVL?

Chair: E. Holler, Germany

16:00-16:15 Yes: M.F. Martelli, Italy

16:15-16:30 No: J.L. Ferrara, USA

16:30-16:45 Discussion

IS PHOTOPHERESIS TREATMENT OF CHOICE FOR CGVHD?

Chair: H.J. Deeg, USA

16:45-17:00 Yes: H. Greinix, Austria

17:00-17:15 No: G. Socié, France

17:15-17:30 Discussion





PRELIMINARY SCIENTIFIC PROGRAM

SATURDAY, SEPTEMBER 10, 2011

HALL A

8:30-10:00 SESSION 8: CORD BLOOD

IS DOUBLE CORD BLOOD TO BE PREFERRED TO A SINGLE UNIT?

Chair: E. Gluckman, France
08:30-08:45 Yes: C. Brunstein, USA
08:45-09:00 No: G. Sanz, Spain
09:00-09:15 Discussion

SHOULD CORD BLOOD UNIT BE SELECTED ACCORDING TO HLA OR CELL-BASED?

Chair: V. Rocha
09:15-09:30 Cell-based: E. Gluckman, France
09:30-09:45 HLA-based: C. Brunstein, USA
09:45-10:00 Discussion

10:00-10:30 Coffee Break

10:30-12:00 SESSION 10: DONOR SELECTION

WHICH IS THE DONOR OF CHOICE IF NO MUD IS AVAILABLE?

Chair: A. Madrigal, UK
10:30-10:45 Haplo: L. Uharek, Germany
10:45-11:00 Cord blood: W. Arcese, Italy
11:00-11:15 Discussion

SHOULD WE EXPAND CORD BLOOD?

Chair: W. Arcese, Italy
11:15-11:30 Yes: G. Sanz, Spain
11:30-11:45 No: V. Rocha, France
11:45-12:00 Discussion

12:00-13:00 Lunch

13:00-14:00 To be announced

14:00-15:30 SESSION 12: LYMPHOMA

AUTOLOGOUS SCT IN FL

Chair: A. Sureda, Spain
14:00-14:15 Yes: C. Gisselbrecht, France
14:15-14:30 No:
14:30-14:45 Discussion

TRANSPLANTATION FOR T-CELL LYMPHOMA

Chair: C. Gisselbrecht, France
14:45-15:00 Pro auto:
15:00-15:15 Pro allo: P. Corradini, Italy
15:15-15:30 Discussion

15:30-16:00 Coffee Break

16:00-17:30 SESSION 14

IS THERE A PLACE FOR ALLO SCT IN TREATMENT OF MM?

Chair: N. Kröger, Germany
16:00-16:15 Yes: G. Gahrton, Sweden
16:15-16:30 No: H. Goldschmidt, Germany
16:30-16:45 Discussion

IS THERE A PLACE FOR ALLO SCT IN HODGKIN'S DISEASE?

Chair: V. Diehl, Germany
16:45-17:00 Yes: A. Sureda, Spain
17:00-17:15 No:
17:15-17:30 Discussion

HALL B

8:30-10:00 SESSION 9

ALLO SCT FOR ELDERLY MYELOFIBROSIS PATIENTS (> 60 Y)

Chair: A. Bacigalupo, Italy
08:30-08:45 Yes: N. Kröger, Germany
08:45-09:00 No: R.A. Mesa, USA
09:00-09:15 Discussion

SHOULD HAPLO-SCT BE PERFORMED WITH T-CELL DEPLETION?

Chair: Y. Reisner, Israel
09:15-09:30 Yes: R. Handgretinger, Germany
09:30-09:45 No: F. Ciceri, Italy
09:45-10:00 Discussion

10:00-10:30 Coffee Break

10:30-12:00 SESSION 11: CELL AND GENE THERAPY

IS SPECIFIC T-CELL THERAPY TARGETING MHAG USEFUL?

Chair: F. Locatelli, Italy
10:30-10:45 Yes: S. Riddell, USA
10:45-11:00 No: M. Bornhäuser, Germany
11:00-11:15 Discussion

GENE THERAPY FOR GENETIC DISEASES (SCID, FA, CGD)

Chair: R. Handgretinger, Germany
11:15-11:30 Yes: M. Cavazzana-Calvo, France
11:30-11:45 No:
11:45-12:00 Discussion

12:00-13:00 Lunch



The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
Berlin, Germany • September 8-11, 2011

PRELIMINARY SCIENTIFIC PROGRAM

SATURDAY, SEPTEMBER 10, 2011

HALL B

14:00-15:30 SESSION 13: CELL THERAPY

T-CELL DEPLETION AND T-CELL ADD BACK

Chair: L. Uharek, Germany

14:00-14:15 Yes: J.H.F. Falkenburg, The Netherlands

14:15-14:30 No:

14:30-14:45 Discussion

MSC FOR GVHD

Chair: M. Bornhäuser, Germany

14:45-15:00 Yes: K. Le Blanc, Sweden

15:00-15:15 No: F. Locatelli, Italy

15:15-15:30 Discussion

15:30-16:00 *Coffee Break*

16:00-17:30 SESSION 15: GVHD

GVHD PREVENTION

Chair: A.R. Zander, Germany

16:00-16:15 Pro ATG: J. Finke, Germany

16:15-16:30 Pro Alemtuzumab: S. Mackinnon, UK

16:30-16:45 Discussion

IS IT POSSIBLE TO SEPARATE GVHD FROM GVL?

Chair: J.L. Ferrara, USA

16:45-17:00 Yes: E. Holler, Germany

17:00-17:15 No: H.J. Deeg, USA

17:15-17:30 Discussion

SUNDAY, SEPTEMBER 11, 2011

HALL A

08:30-10:00 SESSION 16: MYELOMA

SHOULD CR BE TARGET OF THERAPY IN MM?

Chair: J.L. Harousseau, France

08:30-08:45 Yes: S.A. Giralt, USA

08:45-09:00 No: B. Barlogie, USA

09:00-09:15 Discussion

THERAPY POST TRANSPLANTATION IN MM

Chair:

09:15-09:30 Pro consolidation: J.F. San Miguel, Spain

09:30-09:45 Pro maintenance:

09:45-10:00 Discussion

10:00-10:30 *Coffee Break*

10:30-12:00 PLENARY SESSION 18

IS THERE A ROLE FOR ALLO SCT IN STANDARD RISK ALL?

Chair: D. Niederwieser, Germany

10:30-10:45 Yes: J.M. Rowe, Israel

10:45-11:00 No: D. Hoelzer, Germany

11:00-11:15 Discussion

REDUCED OR STANDARD CONDITIONING?

Chair: G. Ehninger, Germany

11:15-11:30 Pro reduced: R. Storb, USA

11:30-11:45 Pro standard: A. Nagler, Israel

11:45-12:00 Discussion

HALL B

08:30-10:00 SESSION 17: INFECTION

SHOULD CMV INFECTION POST ALLO SCT BE TREATED BY CELL- BASED THERAPY?

Chair: S. Riddell, USA

08:30-08:45 Yes: H. Einsele, Germany

08:45-09:00 No: P. Jungman, Sweden

09:00-09:15 Discussion

IS COMBINED ANTIFUNGAL THERAPY MORE EFFICIENT THAN SINGLE AGENT THERAPY?

Chair: H. Einsele, Germany

09:15-09:30 Yes:

09:30-09:45 No: G. Maschmeyer, Germany

09:45-10:00 Discussion



The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
Berlin, Germany • September 8-11, 2011

GENERAL INFORMATION

DATES: September 8-11, 2011

LOCATION: Berlin, Germany

REGISTRATION FEES

	Early Registration Until May 18, 2011	Late Registration May 19 – Aug 31, 2011	From September 1, 2011 and On Site
Participants - Physicians and Scientists	€490	€540	€590
Residents, Nurses, Students	€365	€410	€450
Accompanying Persons		€140	

Registration fees include: Participation in scientific sessions, Congress bag, program and abstract book, all printed material of the Congress, invitation to the Welcome Reception, coffee breaks, lunch on Friday and Saturday.

ACCOMMODATION

ComtecMed is the official travel agent for the International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) and will be offering special reduced rates for accommodation.

LIABILITY AND INSURANCE

The Congress Secretariat and Organizers will not accept liability for personal accidents, nor loss of or damage to private property of participants, either during or directly arising from the International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM). Participants should make their own arrangements with respect to health and travel insurance.



www.comtecmed.com/costem
costem@comtecmed.com

Headquarters and Administration:

53 Rothschild Boulevard,
PO Box 68,
Tel Aviv 61000, Israel
Tel: +972-3-5666166
Fax: +972-3-5666177
Email: info@comtecmed.com

Comtec Spain:

Bailén, 95-97,
pral. 1. a - 08009
Barcelona, Spain
Tel: +34-93-2081145
Fax: +34-93-4579291
Email: spain@comtecmed.com

Comtec China:

175 Xiang Yang Road South,
Shanghai 200031
China
Tel: +86-21-54660460
Fax: +86-21-54660450
Email: china@comtecmed.com

